Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study

FMX101 4%, as a topical foam formulation of minocycline, has been approved by US Food and Drug Administration for the treatment of moderate-to-severe acne vulgaris (AV).